BACKGROUND: Regadenoson during exercise stress test (ETT) can provide maximal hyperemia for myocardial perfusion imaging (MPI), along with exercise information. Our aim was to study the feasibility and safety of regadenoson injection at peak ETT for submaximal heart rate (HR) response. METHODS: Consecutive patients who underwent SPECT MPI with standard Bruce ETT or supine-regadenoson (Supine-Reg) were analyzed. ETT patients were grouped as ETT-Max [maximal HR > 0.85 * (220 - age), N = 1,522], ETT-Submax (submaximal HR no regadenoson, N = 504), ETT-Reg (submaximal HR and regadenoson, N = 211). RESULTS: The HR during ETT was submaximal in 715 (32%) patients. Of these, 211 patients (30%) underwent ETT-Reg (mean exercise duration: 5.5 ± 2.5 minutes). ETT-Reg patients had a higher frequency of hypertension, diabetes, smoking and beta-blocker use, similar rest systolic blood pressure (SBP), but lower rest and peak HR and peak SBP compared to ETT-Max patients. There were no serious complications with regadenoson. Side effects (49% vs 6%, P < .0001) were fewer and aminophylline use was lower with ETT-Reg compared to Supine-Reg (0.5% vs 8.1%, P = .001). CONCLUSIONS: Submaximal HR response to ETT is common. ETT-Reg is safe, feasible, and well-tolerated. ETT-Reg facilitates a diagnostic MPI with reporting of functional capacity, exercise ECG/hemodynamic changes and MPI at maximal hyperemia.
BACKGROUND:Regadenoson during exercise stress test (ETT) can provide maximal hyperemia for myocardial perfusion imaging (MPI), along with exercise information. Our aim was to study the feasibility and safety of regadenoson injection at peak ETT for submaximal heart rate (HR) response. METHODS: Consecutive patients who underwent SPECT MPI with standard Bruce ETT or supine-regadenoson (Supine-Reg) were analyzed. ETTpatients were grouped as ETT-Max [maximal HR > 0.85 * (220 - age), N = 1,522], ETT-Submax (submaximal HR no regadenoson, N = 504), ETT-Reg (submaximal HR and regadenoson, N = 211). RESULTS: The HR during ETT was submaximal in 715 (32%) patients. Of these, 211 patients (30%) underwent ETT-Reg (mean exercise duration: 5.5 ± 2.5 minutes). ETT-Regpatients had a higher frequency of hypertension, diabetes, smoking and beta-blocker use, similar rest systolic blood pressure (SBP), but lower rest and peak HR and peak SBP compared to ETT-Max patients. There were no serious complications with regadenoson. Side effects (49% vs 6%, P < .0001) were fewer and aminophylline use was lower with ETT-Reg compared to Supine-Reg (0.5% vs 8.1%, P = .001). CONCLUSIONS: Submaximal HR response to ETT is common. ETT-Reg is safe, feasible, and well-tolerated. ETT-Reg facilitates a diagnostic MPI with reporting of functional capacity, exercise ECG/hemodynamic changes and MPI at maximal hyperemia.
Authors: Martha Gulati; Henry R Black; Leslee J Shaw; Morton F Arnsdorf; C Noel Bairey Merz; Michael S Lauer; Thomas H Marwick; Dilip K Pandey; Roxanne H Wicklund; Ronald A Thisted Journal: N Engl J Med Date: 2005-08-04 Impact factor: 91.245
Authors: Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber Journal: J Nucl Cardiol Date: 2010-04-23 Impact factor: 5.952
Authors: Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang Journal: J Nucl Cardiol Date: 2007 Sep-Oct Impact factor: 5.952
Authors: Andrea De Lorenzo; James Foerster; Maria G Sciammarella; Cathy Suey; Sean W Hayes; John D Friedman; Daniel S Berman Journal: J Nucl Cardiol Date: 2003 Jan-Feb Impact factor: 5.952
Authors: Thomas A Holly; Aaron Satran; David S Bromet; Jennifer H Mieres; Martin J Frey; Michael D Elliott; Gary V Heller; Robert C Hendel Journal: J Nucl Cardiol Date: 2003 May-Jun Impact factor: 5.952
Authors: Randall C Thompson; Harshal Patil; Elaine C Thompson; Gregory S Thomas; Mohammed Al-Amoodi; Kevin F Kennedy; Kevin A Bybee; A Iain McGhie; James H O'Keefe; Lisa Oakes; Timothy M Bateman Journal: J Nucl Cardiol Date: 2012-12-12 Impact factor: 5.952